Terray Therapeutics
Terray Therapeutics is an AI-powered biotechnology company focused on revolutionizing small molecule drug discovery. Their platform, tNova, uniquely integrates high-throughput chemical experimentation with computational analysis and generative AI. This approach emphasizes both wet lab science and AI to solve complex therapeutic challenges. Terray boasts an experimental dataset of over two billion binding measurements, growing by 300 million monthly, with each measurement supported by 25 independent data points for high-resolution quantitative data. Their closed-loop iteration cycle, completing in under a month, allows for rapid exploration of chemical space and experimental measurement of millions of molecules. Terray's internal pipeline targets immunology, and they partner with large pharma and biotech companies to apply their platform to a wide range of challenging targets and therapeutic areas.
Terray Therapeutics
Terray Therapeutics is an AI-powered biotechnology company focused on revolutionizing small molecule drug discovery. Their platform, tNova, uniquely integrates high-throughput chemical experimentation with computational analysis and generative AI. This approach emphasizes both wet lab science and AI to solve complex therapeutic challenges. Terray boasts an experimental dataset of over two billion binding measurements, growing by 300 million monthly, with each measurement supported by 25 independent data points for high-resolution quantitative data. Their closed-loop iteration cycle, completing in under a month, allows for rapid exploration of chemical space and experimental measurement of millions of molecules. Terray's internal pipeline targets immunology, and they partner with large pharma and biotech companies to apply their platform to a wide range of challenging targets and therapeutic areas.
TL;DR
What they do: AI-powered, chemistry-first platform (tNova / EMMI) for small-molecule drug discovery combining high-throughput experimental chemistry and generative AI
Data scale: Experimental dataset of over two billion target–ligand binding measurements, growing rapidly
Funding: Raised >$200M total; $120M Series B announced Oct 17, 2024
Focus areas: Internal immunology programs and partnered programs with large pharma
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |